PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023

Report Back from SGO 2023: What’s New in Ovarian Cancer?Подробнее

PARP inhibitors and ovarian cancerПодробнее

Updates in PARP inhibition for ovarian cancerПодробнее

PARP inhibitors for ovarian cancerПодробнее

An Overview of PARP Inhibitors in Ovarian CancerПодробнее

2023 Ovarian Cancer Clinical UpdatesПодробнее

PARP inhibitors as first-line maintenance therapy in ovarian cancerПодробнее

Overcoming resistance to PARP inhibition in ovarian cancerПодробнее

Ongoing Clinical Trials with PARP Inhibitors in Ovarian CancerПодробнее

PARP Inhibitors in Ovarian Cancer Treatment | Webinar | Ambry GeneticsПодробнее

Report Back from SGO: What’s the Latest in Ovarian Cancer?Подробнее

Navigating Rapid Change in Ovarian Cancer: PARP Inhibitors in Clinical PathwaysПодробнее

Ovarian Cancer Symposium 2021: Session 4 PARP InhibitorsПодробнее

Assessing the role of PARP inhibitors and immunotherapy in ovarian cancerПодробнее

PARP Inhibition Improves Outcomes in Patients With BRCA-Mutated Ovarian CancerПодробнее

2024 Gynecologic Cancer Update: What's New in Ovarian & Gynecologic Cancers (2024)Подробнее

Update on PARP inhibitors in Ovarian and Pancreatic CancerПодробнее

Dr. Crafton on the Impact of PARP Inhibitors in Recurrent Ovarian CancerПодробнее

Expert Perspectives: The Clinical Potential of PARP Inhibitors in Ovarian CancerПодробнее